ペプチドリーム株式会社 News Releases

PeptiDream, PDR Pharma, and Curium Complete Patient Administration in Domestic Clinical Trial for Prostate Cancer Diagnostic Candidate 64Cu-PSMA-I&T

PeptiDream, PDR Pharma, and Curium announced the completion of patient administration in a domestic … · 2026-06-11

Peptidream Announces First Administration in a Specific Clinical Study of Cancer Radiopharmaceutical Candidate 64Cu-PD-29875 Targeting Claudin18.2 in Gastric Cancer Patients

Peptidream Inc. has administered the first dose to a subject in a specific clinical study of its can… · 2026-06-11